High dimensional digital pathology to investigate the tumor micro environment and its impact on response to therapy

高维数字病理学研究肿瘤微环境及其对治疗反应的影响

• 批准号: 10246402
• 负责人: Zoltan Maliga
• 金额: $ 21.55万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10246402
• 关键词: Adverse reactions; Antibodies; Atlases; Autoimmune Diseases; Biological Markers; Cells; Cutaneous; Data Analyses; Detection; Development; Disease; Doctor of Philosophy; Environment; Funding; Grant; Human; Image; Immune; Immunofluorescence Immunologic; In Situ Hybridization; Inflammation; Laboratories; Malignant Neoplasms; Manuscripts; Methods; Mus; Oligonucleotides; Pathology; Periodicity; Pharmacology; Pharmacotherapy; Process; Reagent; Reporting; Research; Research Personnel; Research Project Grants; Resolution; Sampling; Scientist; Senior Scientist; Skin; Specialist; Stains; Supervision; System; Technology; Tissue imaging; Tissues; United States National Institutes of Health; Work; Writing; base; career development; cellular imaging; digital pathology; high dimensionality; medical schools; melanoma; member; multiplexed imaging; programs; response; skin organogenesis; tumor; tumor microenvironment

Summary Grant: Research Specialist (PAR-19-291) Under the supervision of senior scientist Zoltan Maliga PhD, investigators and staff at the Harvard Medical School Laboratory of Systems Pharmacology (LSP) will contribute to cell and tissue imaging and analysis for U2C and U54 program grants LSP-based investigators will perform the tissue-based cyclic immunofluorescence (t-CyCIF) method developed at HMS on FFPE human and mouse skin samples provided by investigators and will work together to define and validate antibodies to stain biomarkers of skin development, inflammation, melanoma progression and tumor microenvironment and will share technologies under development to further advance the t-CyCIF method (e.g. switch to six-channel imaging, use of oligo-modified antibodies as detection reagents, combination of in situ hybridization or sequencing methods). The LSP will process t-CyCIF images, provide quantitative cell and tissue-level analysis and help distribute high-resolution multiplexed images as part of a disease pathology atlas. Maliga will work with PIs Lian, Murphy, LeBoeuf, Haigis, Aster to prepare manuscripts, write reports for the NIH and collaborate with other members of the project teams as required the by PAR-19-291.

摘要 格兰特：研究专家(PAR-19-291) 在资深科学家佐尔坦·马里加博士的监督下，哈佛大学的研究人员和工作人员 医学院系统药理学实验室(LSP)将为细胞和组织成像做出贡献 以及对U2C和U54计划拨款的分析 基于LSP的研究人员将执行基于组织的循环免疫荧光(t-CyCIF)方法 在研究人员提供的FFPE人和小鼠皮肤样本上由HMS开发，并将发挥作用 共同定义和验证抗体以染色皮肤发育、炎症、 黑色素瘤进展和肿瘤微环境，并将分享正在开发的技术 为了进一步推进t-CyCIF方法(例如，切换到六通道成像，使用寡聚修饰的 抗体作为检测试剂，结合原位杂交或测序方法)。这个 LSP将处理t-CyCIF图像，提供定量的细胞和组织水平分析和帮助 分发高分辨率多路复用图像，作为疾病病理图集的一部分。 马利加将与Pis Lian，Murphy，LeBoeuf，Haigis，Aster一起准备手稿，撰写报告 并根据PAR-19-291的要求与项目团队的其他成员合作。